Work
About
Work
About
E-scooters at a crossroads
E-scooters at a crossroads

Posts Tagged ‘health’

Unravelling the Budget – Health and Life Sciences reflections

Alongside the economy, health is one of the top concerns among the electorate. In today’s Budget, likely to be the last before the General Election, the Chancellor made announcements which will have implications for the healthcare system and clients alike. 

Here, we take a look at three key take aways for the health and life sciences industry:

An efficiency saving trade-off for the NHS 

The Chancellor’s flagship Budget announcements were largely based on personal finances. This includes a 2p cut to national insurance tax, freezing fuel duty, and raising the child benefit cap. Despite this, Hunt did find room for one significant financial package for the NHS – £3.4 billion of funding towards the NHS Productivity Plan.  

The Productivity Plan aims to fund digital advancements across the board, including for AI MRI scanners, ungraded IT systems and digitally enabled prevention services. The plan will also fund electronic patient records in all NHS trusts by 2026 – something initially committed to by Hunt when he was Health Secretary in 2013.  

This funding package and the commitments attached to it should be welcomed; however, they will be delivered alongside an expectation that the NHS achieves annual productivity growth of 2%. In the wake of ongoing industrial action and the largest real terms cut to NHS funding since the 1970s, this may be difficult to achieve.  

Clients engaging with the NHS should bear this in mind – policies and proposals that offer productivity gains or efficiency savings will be warmly welcomed.  

Scuppering Labour 

Hunt’s unexpected decision to reform the non-dom tax status takes away the only funding source for Labour’s health service reform plans, just as they will have finalised their manifesto commitments.  

Shadow Health Secretary Wes Streeting confirmed yesterday that this leaves a hole in their funding allocation, and they would have to look at alternatives. Hunt’s decision to act here puts a sizeable spanner in the works for Labour’s health mission.  

While there is nothing to suggest that Labour are inclined to move in an entirely new direction, this new development will likely require them to consider their priorities and rethink their direction of travel in health policy.  

What about Life Sciences?  

Hunt’s budget this year reaffirmed the Government’s position placing Life Sciences as a key growth sector in a series of announcements including funding for medical research charities and R&D tax reliefs. He hailed the success of AstraZeneca’s £650m investment in R&D and manufacturing sites in Cambridge and Liverpool respectively. 

Richard Torbett, CEO of the ABPI, suggested that this shows UK medicine manufacturing can be reinvigorated if the policy environment is right. The policy environment he refers to is one that values growth, jobs and investment.  

This is a mindset shared with Labour. Attracting Life Sciences industry investment is central to their plan for the sector and wider ambitions for growth. Any opportunity to leverage home-grown domestic growth and inward investment will be looked on favourably.   

Share this content:

Five key takeaways: Engaging with ICS priorities panel session

WA was delighted to host a panel session with Dr Layla McCay, Director of Policy and NHS Confederation and Mike Bell, Chair of NHS South West London integrated care board (ICB) and WA Health Senior Adviser.  

At the session, WA’s Head of Health, Dean Sowman, explored Layla and Mike’s perspectives on how the life sciences industry can meaningfully engage with, and play a role in delivering integrated care systems (ICS) priorities. 

In light of a 30% cut to operating budgets and industrial action absorbing the bandwidth of executive teams, ICSs are currently heavily focused on short-term operational priorities. We have outlined five key factors to engage effectively against this backdrop:   

1. ICSs are delaying some action until the general election 

Whilst both the Labour and Conservative parties have communicated support and optimism for ICSs, the reality is that political uncertainty and operational pressures mean that many ICBs have little bandwidth to implement their ICB led five-year joint forward plan.  

Instead, ICSs are increasingly deferring important decisions until there is a stable administration which can ensure the preservation of essential funding and objectives. The overarching concern is that the exact vision of ICS working to respond to local population needs will be overshadowed by national pressures.    

Whilst this is a considerable challenge, the take home message for organisations looking to engage is the importance of timing the hope is that following the winter period, which is a particularly politically sensitive time, ICSs will have greater bandwidth to begin to implement their strategies.  

2. There’s no shortcut to engaging with all ICSs, and no one-size fits all approach 

When looking to secure policy changes, there is currently no shortcut to speaking to all 42 ICSs. We are starting to see some ICSs coalescing or developing strategic multi-ICB structures where some ICBs lead on certain workstreams on behalf of others. This trend is likely to become more commonplace – so engagement may become more streamlined in the future.  

For now, the best route to engage with multiple ICSs comes through existing forums, including NHS Confederation’s ICS network and NHSE’s Academic Health Science Networks (AHSN) 

3. Medicines optimisation and management is a priority with positive examples needed  

One key barrier to ensuring medicines optimisation is that current financial models are created to show benefits to local service providers – some of which are not covered by ICS budgets. There needs to be an overhaul of where the service is delivered, where the money flows and where the savings are realised. While there is clarity on this being a problem – at present there is no solution.  

NHS Confederation would welcome examples of impactful collaborations between ICSs and industry as there is currently a shortfall of tangible examples.  

4. New evidence and ideas to support the delegation of specialised commissioning are welcomed  

The delegation of specialised commissioning to ICSs remains a concern. Prescribing budgets will remain with NHS England, but services deemed ready for integration will be delivered locally. There are outstanding questions as to whether individual ICSs are equipped with the right workforce and expertise, and what multi-ICB structures could be formed.  

This is especially pertinent in the case of rare diseases. Given their low prevalence in local areas, rare diseases are unlikely to be a core focus for ICSs, as evidenced by WA’s analysis which found that just five of the ICB five-year plans featured rare diseases.  

However, there is optimism that the transfer of specialised commissioning responsibilities offers the opportunity for a reset. If done right, it could ensure the repurposing of specialised commissioning budgets across the whole pathway, challenging local systems to reduce spend on tertiary services, and instead finding new ways to act earlier.  

5. Understanding where each ICS is placing strategic emphasis is critical 

Each ICS is at a different stage of maturity and there is distinct variation in size, scale and local characteristics, meaning a one-size fits all approach to engagement will not work. As a first step, understanding where you may wish to begin engagement and how to frame this in line with local priorities is essential. 

At the end of June 2023, 40 of the 42 ICBs had published their five-year joint forward plans setting out their strategic vision to tackle the health issues faced by their local population.  

To support industry, WA has undertaken an in-depth analysis of the plans to create an interactive map showing the level of priority each ICB is placing across 27 themes. Understanding the ICBs that are prioritising your areas of interest, can support you in identifying meaningful collaborations and partnerships aligned to an ICB goals. 

About WA Communications 

WA Communications is an integrated strategic communications and public affairs consultancy. Our specialist health practice supports clients across a diverse range of diseases at the intersection of policy, government affairs and communications, to achieve their strategic objectives. 

If you would like to discuss how to best work in partnership with Integrated Care Systems, and our analysis of their key areas of focus, contact Lloyd Tingley atlloydtingley@wacomms.co.uk. 

 

 

 

 

Share this content:

Scottish National Priority: how the SNP leadership contest could shape the NHS

This SNP leadership election will, for the first time in almost a decade put a new face at the forefront of Scottish politics.

While independence is unsurprisingly at the top of the agenda for the candidates, healthcare is a key battleground: a recent Ipsos poll found the NHS is the issue of greatest concern for Scottish voters.

Scotland is facing a healthcare crisis. The gap in life expectancy between the least and most deprived areas now stands at 13.3 years for men and 9.8 years for women, A&E waiting times are increasing, and the Government is set to miss key targets this year in NHS recruitment and tackling elective waiting lists.

How do the leadership candidates plan to address the healthcare crisis?

Humza Yousaf

With almost two years of health and social care experience under his belt, Humza Yousaf expectedly has the most developed set of healthcare policy goals, stating that he will make the NHS a priority as First Minister. As such, his ability to follow through on campaign commitments will be closely scrutinised if he is selected at the end of March.

Kate Forbes

Kate Forbes has also leant on her experience as Finance Secretary for the policy basis of her campaign.

Uniting both Forbes and Yousaf is their commitment to delivering the controversial National Care Service, an NHS-style centrally managed care service pitched as a solution to social care. Scottish Labour has framed the plans as a ‘power grab’ from local authorities; however, given the state of the social care sector across the rest of the UK, the SNP’s ‘top two’ are eager to promote Scotland’s solution.

Ash Regan

Despite being the clear underdog in the contest, the third and final leadership candidate, Ash Regan, proposes solutions that demonstrate the political breadth of the SNP.

While Ash Regan is unlikely to triumph in the contest, she represents the scale of the challenge that Kate Forbes or Humza Yousaf will have in uniting the Party to tackle the issue of greatest concern to Scottish voters, and the broad spectrum of policy ideas that lie within it.

Regardless of who is voted in as Party leader, the Health and Social Care in-tray will be busier than every other department. Before the next General Election, the incoming First Minister, and their new Health and Social Care Minister will need to drive significant improvements in healthcare if they want to have any chance of matching the flawless electoral performance of their predecessor.

Share this content:

Spring Budget: warm words, limited progress for the life sciences industry

It is no surprise that the Chancellor called out the importance of the life sciences industry to the UK in today’s Spring Budget. Intensive industry engagement over recent months made its inclusion as a critical industry inevitable.

During his lengthy speech, he gave a few positive signals on the Government’s intent to boost the sector. He went out of his way to praise industry, particularly for its role during the pandemic, before making two new headline announcements.

First, Hunt announced an enhanced tax credit scheme for small and medium sized R&D businesses.

20,000 companies will receive £27 for every £100 they spend. This has already been celebrated by the UK BioIndustry Association (BIA), and is clear recognition of the need to do more to support biotech companies to develop breakthrough treatments in the UK.

Second, he announced new reforms to regulatory approvals in an attempt to speed up access to innovative treatments.

From 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) will allow for fast-track approval of medicines and technologies already approved by trusted international regulators, such as the US, Europe and Japan.

The intention is to support companies to bring innovative treatments to patients faster, while encouraging further investment and priority launches in the UK.

This announcement comes as industry has become increasingly vocal over their concerns that the UK is losing ground as a launch market. In 2023 alone, AstraZeneca cited a sub-optimal business climate as the main reason for building a new $400m plant in Ireland, instead of the UK, and AbbVie and Eli Lilly exited the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

This pressure has clearly cut-through, and industry should be pleased their voice is being heard.

But, will this new MHRA process actually make the difference the Government hopes and change the direction of travel? Potentially not.

As heralded by Hunt in his speech, the MHRA was the first in the world to approve a vaccine for COVID-19. The regulator is already efficient and new schemes to speed up regulatory approval, such as Project Orbis and the Innovative Licensing and Access Pathway (ILAP), are already in place.

The biggest barrier to providing swift access to innovative treatments is NICE’s capacity to swiftly appraise the increasing volume of company submissions, and the subsequent potential for protracted negotiations with NHS England. Quicker licensing will do nothing if the resource and full system alignment are not in place.

There are also questions around how the process will be implemented. It could easily become a perverse incentive, with companies prioritising regulators with more appealing launch markets, such as the FDA, in the knowledge that the MHRA will fall in behind any license anyway.

It would also be naïve to view any announcement of this kind outside of challenging VPAS negotiations, kicking off in earnest this month as the ABPI set out their proposal of a 6.88% fixed rebate rate, which was swiftly, and strongly rebuffed by both the Department of Health and Social Care and NHS England. Ultimately, companies remain deeply concerned about the attractiveness of the UK.

Labour could steal a march if they take a bolder, whole medicines pathway approach to access. Because while it is a good sign that the Government still acknowledges the critical importance of the life sciences sector, whether the bigger issues are addressed any time soon remains to be seen.

Share this content:

Boris Johnson is Safe… For Now

On the surface Boris Johnson commands the support of nearly all his MPs. He will derive some comfort from this public display of loyalty. In terms of his future, the relationship with the Conservative parliamentary party is all that matters. Quite a lot of voters may tell pollsters that they regard Johnson as a ‘liar’. Normally calm constitutional historians and Archbishops may fume. Parts of the media and Twitter can be in uproar. But, as long as Johnson keeps his MPs on board he can carry on. The power to remove him lies with Tory MPs alone. During his post-Easter statement to the Commons, the first since he received his penalty notice for the birthday party in Number Ten, only one backbencher called on him to go.

But the surface does not tell the whole story. Over the bank holiday I phoned several Tory MPs including a few who are uneasy about  their Prime Minister becoming a ‘law breaker’. They told me they would not contemplate for a single second speaking out in public against Johnson before the local elections. Their party members are spending their spare time campaigning energetically and they would not undermine such effort by condemning their party leader. They would never be forgiven by activists if they did so. In other words the May local elections are a big protective shield for Johnson and also a threat. In advance of the vote, quite a lot of Tory MPs feel they have no choice but to suspend judgement. Any critical quotes would help Labour. That does not mean their support is guaranteed if the Conservatives perform poorly in the elections.

As has been the case since ‘partygate’ erupted, the mood of the Tory doubters in the parliamentary party fluctuates on a near daily basis. There have been times when they were ready to make a move against Johnson. On other occasions they are resolved not to do so. Ukraine is another factor fuelling the changing judgements, although from my conversations this is becoming less potent compared with the fact that that important elections loom. Political parties are at their most tribal during a campaign. There is another reason why the mood constantly changes. Many of the MPs, especially those from the ‘red wall’, are new to national politics. Suddenly they face the most daunting of decisions, whether or not to remove a Prime Minister. They do not quite know what to think or what to do.

In reality the parliamentary party divides into three sections. There are the Johnson loyalists who will stick with him even if he receives more penalty notices and the Sue Gray report is damning. There is a tiny minority for now calling for him to go. In the middle there is a significant section waiting to see what happens next. That includes some ministers who are unsure how this is going to play out. All are loyal for the time being except for the significant resignation last week of Lord Woolfson, a Justice Minister. It’s easier for peers to resign when local elections are being contested. They are above the electoral fray. In some cases Johnson cannot assume that loyalty will endure across the government after the May elections.

The strategy in Number Ten, a more nimble operation after recent changes, is clear. They call for “perspective” as Johnson focuses on Ukraine, the cost of living crisis and his plans for dealing with the migrant crisis. Johnson’s every move is made with his own survival in mind. He and his new inner circle know he is not safe yet. Johnson seeks to be the indispensable ‘man of action’, visiting Kiev earlier this month and off to India this week. After his act of contrition in the Commons he delivered a different more upbeat performance to his own MPs at a private meeting, linking his plan to send migrants to Rwanda with an attack on the BBC and the Archbishop of Canterbury, suggesting they were soft on Putin. This is a classic Johnson tactic, seeking to tick several boxes in a single assertion. He knows most of his MPs approve of the Rwanda scheme, admire his approach to Putin and are angry about the BBC and the Archbishop. After the May elections Johnson plans to unveil a Queen’s Speech that will again be aimed at pleasing his MPs with bills on ‘levelling up’ and other legislative items that he will claim represents the ‘people’s priorities’.

But Johnson and his advisers are not wholly in control of events. The metropolitan police investigation continues without any indication of which party is being scrutinised and when the next penalty notices will be handed out. No one in Number Ten knows when the investigation will end. When it does the Gray report will be published and, on the basis of her interim findings published earlier this year, it will be damning. In his Commons’ statement Johnson focused only on the Number Ten birthday party. If charged for other events he will have to find new explanations. Johnson has a distinct capacity for climbing out of deep holes. But he is not entirely lacking in self-awareness. Indeed he can be introspective and melancholic at times. Mostly I hear from his allies how he is robustly determined to keep going  but one did note that this crisis is getting Johnson down. With his ‘Churchillian’ sense of destiny, being the first prime ministerial law breaker was not meant to be part of the narrative.

The context is as much a key to his fate as the scale of the law-breaking. If the Conservatives do badly in the local elections and Labour soar, Tory MPs will begin to worry about whether they will lose their seats. The elections next month might not be as clear cut as that. They rarely are. But then there is the Wakefield by-election probably to be held later in the summer, a big test for both Johnson and Keir Starmer.

There are some other big themes that will dominate the coming months. The IMF has forecast that the UK economy will suffer the weakest growth out of the G7 countries. Rising inflation is destabilising for even the strongest of governments and the Johnson administration is fragile. The collapse in the standing of Rishi Sunak might have removed a leadership rival but any government needs a Chancellor with authority when the economy is weak. The dynamic between Johnson and Sunak will be pivotal. At the moment both are vulnerable. Usually one has been in a stronger position than the other. Sunak’s spring statement was framed when the Chancellor was at his most assertive as Johnson fought for his political life. In the past Johnson’s deeper interventionist  instincts have tended to win out because he was in a strong enough position to prevail over his Chancellor. For now at least they dance together after Sunak decided to stay on rather than resign after receiving his penalty notice and with Johnson currently too weak to sack him. If Johnson emerges safely from ‘partygate’ he might be tempted to appoint another chancellor, but none of the options are straightforward. The likes of Liz Truss and Sajid Javid share Sunak’s fiscal conservatism. Javid’s tax affairs are also attracting media interest.

For whoever is Prime Minister and Chancellor this autumn, the budget will be a moment of great significance for the economy and the future of this government. There could well be a further economic statement from Sunak this summer although he is keen to avoid one, wanting to focus on his budget and not give the impression of ‘panic’ reactions before then. Sunak has spent some time studying what happened in the 1970s when inflation raged more wildly than now. He noted that there were endless emergency budgets that tended to fuel further panic.

Even so the autumn is a long way off. There will be many twists and turns before then.

Share this content:

Are women finally being heard?

Women in the UK are becoming increasingly vocal about the challenges they face in their healthcare and the unjust variation in access to services. When the Government opened their consultation to inform a Women’s Health Strategy in Spring 2021, over 110,000 respondents took the opportunity to make it known that the system does not work for them. Following years of campaigning, it comes as no surprise to women and those in the women’s health community that an overwhelming 84% of people felt their voices are simply not being heard when they seek health care.

By demonstrating an interest in women’s voices and their experiences, recognising failures in the system, and committing to developing a Women’s Health strategy, the Government has taken a positive initial step, albeit an ambitious one. There is no disease-specific focus and no target patient population, unlike other policy areas. This challenge affects 51% of our population and includes natural, life course events that women have, for many years, been told to just live with. With publication of the strategy imminent, the Government now need to demonstrate that they are willing to not only listen to women’s voices but to implement action based on what they are saying.

Women continue to face challenges when it comes to choices about their own bodies. Ongoing variation in access to abortion care, a full range of contraceptive choice, and a holistic range of menopause treatment options, all impact on women’s freedom to choose the treatments that work best for them. The Government’s commitment to prioritising the menopause in the upcoming strategy and cutting prescription costs for Hormone Replacement Therapies (HRT) in response to the Menopause Revolution campaign is hopeful. However, the Government’s initial attempt to reverse progress made in at-home abortion during the pandemic despite women citing a clear preference for this to continue, suggests more need to be done to prioritise women’s voices, choices and rights in practice.

In addition to not being heard, a fragmented system and the pandemic backlog have resulted in services that are increasingly difficult to navigate, leading to the most vulnerable falling through the cracks. Upcoming system reforms focusing on the integration of care offer opportunities to take a patient centered approach and reduce inequalities in outcomes. The Government is also expected to advocate for the establishment of ‘women’s health hubs’, which aim to enable access to all required care in a one-stop shop, in line with calls from advocates including the Primary Care Women’s Health Forum and Royal College of Obstetricians and Gynaecologists. Despite the promise of better integration locally, fragmentation is continuing at a national level. Abortion has been removed from the Women’s Health Strategy and is expected to feature in the upcoming Sexual Health Strategy. With a wider interest in health inequalities, the Government must recognise the connection between these elements of healthcare and align planning nationally to support local areas to integrate care.

Committing to a women’s health strategy is a promising step in the right direction for this Government and has offered women long overdue hope. Action in response to prominent campaigns, such as the Menopause Revolution, to change the way women can interact with the system allow us to believe that the challenges women have faced for far too long could be overcome within their lifetime.

The Government have a real opportunity to ensure women have their voices heard. To do this, they must recognise the challenges they face, capitalise on system reforms to integrate care, collaborate with the women’s health community, and most importantly, commit to funding appropriate and immediate action. In a health system and economy designed by and for men, the time for meaningful, impactful change, is now.

Share this content:

WA Investor Services supports Agathos’ investment in Hunter Healthcare

WA Investor Services is proud to announce it has supported Agathos’ acquisition of Hunter Healthcare, a specialist recruiter working across the healthcare and life sciences sectors. The investment will help support Hunter’s ambitious growth plans, providing vital staffing solutions to healthcare providers and medical researchers, including developing its offer in international markets.

WA provided political due diligence to support the transaction, with its team of healthcare policy experts providing insights integral to the deal process, working closely with Agathos and other due diligence providers to deliver clarity on how ongoing structural changes to the NHS, the elective recovery and acceleration of the digital transformation agenda will affect healthcare recruitment decisions and priorities.

Commenting on the deal, WA Partner and Head of Investor Services Lizzie Wills said: “We are extremely pleased to have worked with Agathos on this deal. NHS staffing is a very high-profile issue at the moment and ensuring the NHS meets patient demand while undertaking fundamental system reform is a priority for political and NHS leaders, not least as they tackle the post-Covid backlog. As a market leading provider of political due diligence in healthcare transactions we were in an extremely strong position to support Agathos’ successful deal and we look forward to seeing the business develop over the coming years.”

Hugh Costello, Investment Director at Agathos said: “WA Comms produced a comprehensive report with insightful conclusions that were well supported by desktop research and interviews with sector participants. The team was available for calls as and when required and were always a total pleasure to deal with. Ultimately, the output produced by WA was instrumental in our decision to complete our investment. I would recommend their services wholeheartedly.”

Share this content:

WA Investor Services supports Livingbridge’s investment in Everlight

WA Investor Services is proud to announce it has supported Livingbridge’s acquisition of Everlight, an innovative 24-hour teleradiology business. Livingbridge’s investment will help support Everlight in building its pool of exceptional radiologists, driving technological innovation and propelling international growth.

WA provided political due diligence to support the transaction, with its team of specialist political risk analysts assessing the impact of structural changes in the NHS on the business, NHS strategies for recovering from the Covid-19 pandemic, and the potential implications of long-term workforce and technological issues affecting the sector.

Commenting on the deal, WA Partner and Head of Investor Services Lizzie Wills said: “We are extremely pleased to have worked with Livingbridge on this deal. Everlight is very well placed to assist the NHS in delivering cost-effective, high quality services and providing much needed capacity at a time when the health service is experiencing unprecedented demand.  Our market leading expertise in the health sector put us in a strong position to support Livingbridge’s successful deal and we look forward to seeing the business develop over the coming years.”

Share this content:

WA Investor Services supports Livingbridge’s investment in AJM Healthcare

WA Investor Services is proud to announce it has supported Livingbridge’s investment in AJM Healthcare, a leading provider of NHS wheelchair services. The investment will help support AJM’s continued growth, enabling more users to benefit from its innovative, comprehensive and tailored solutions.

WA provided political due diligence to support the transaction, drawing on its market-leading expertise of evolving NHS commissioning policy, changes to the government’s procurement processes, and the wider reform agenda for health and social care. This insight was supported by the views of key decision makers and policy influencers from across WA’s extensive network.

Commenting on the deal, WA Partner and Head of Investor Services Lizzie Wills said: “We were delighted to support Livingbridge on this deal, at a time when the NHS is going through a substantial period of change. The restructuring of the commissioning process and the government’s wider focus on reform in the sector will have a significant impact on all businesses working in health and social care. WA’s deep network in both government and the NHS has informed our understanding of what the new landscape will look like and allowed us to generate valuable insights for Livingbridge. Our congratulations to everyone involved in the deal; we look forward to seeing AJM go from strength to strength in the years ahead.”

Share this content:

Webinar – Balancing the health of the nation with the health of the economy

On Thursday 15th October 2020, WA Communications Director, Caroline Gordon, hosted a webinar exploring how the Government can balance the health of the nation with the health of the economy.

We are living through unprecedented times in which a devastating public health crisis is creating a global economic slowdown.

The Government has to make daily decisions that balance the health of the nation against the health of our economy. Political, media and public pressure is building and a difficult winter is approaching. There are no easy answers – just more questions facing every business and organisation in the UK as to how to respond, plan and communicate.

Panellists included:

 

Watch a recording of the webinar:

 

 

 

 

Share this content:

Novo Nordisk chooses WA Communications for diabetes brief

WA Communications’ growing health team has been chosen by leading diabetes company Novo Nordisk to drive government affairs in their diabetes business, making the first half of 2020 WA Health’s most successful period to date.

WA Health won a competitive pitch to secure the retained account with Novo Nordisk, supporting the company with their innovative type 2 diabetes portfolio. Head of Health Caroline Gordon will lead the account alongside Associate Director Dean Sowman, working to Dan Beety, Director of Corporate Affairs at Novo Nordisk.

Dan Beety of Novo Nordisk said:

‘‘We put in place a rigorous selection process and were impressed by Caroline and her team. WA’s insight, commitment and enthusiasm shone through. Their approach brought creative ideas that showed a deep understanding of what we’re trying to achieve.”

The wins cap off a strong first half of 2020 for WA’s health team, who also recently won a five way competitive pitch to work with Sanofi’s rare disease franchise.

Earlier this month, WA Communications also won the coveted CIPR Consultancy of the Year award.

To talk to Caroline about your business needs, please get in touch via carolinegordon@wacomms.co.uk.

 

 

Share this content:

Mental Health MPs’ top priority according to new poll for WA

Research from WA Communications on the health priorities of the new parliament has found that 62 per cent of MPs see mental health as the top priority for health spending over the next five years.

The research, informed by a cross-party YouGov poll of 100 parliamentarians, finds that more MPs selected mental health spending as a top three priority than any other condition, coming ahead of cancer care (selected by 35 per cent), cardiovascular (14 per cent) and diabetes (8 per cent).

The findings reflect the political prominence of mental health over the past few years with all major parties placing it core to their health plans. Yet a significant gap between the parties exists, with 80% of Labour MPs placing it as their top priority, in contrast to 47% of Conservative MPs.

Cancer care, traditionally a key political health issue, falls behind mental health overall, but is still viewed by more than a third of MPs as one of the top three priority areas for NHS funding. Conservative MPs identified cancer care as the area they would most like to see money spent on, with almost half (46%) selecting this.

This is despite Conservative Party plans to broaden the scope of the Cancer Drugs Fund into an Innovative Medicines Fund to support other areas such as autoimmune and rare diseases.

Prevention agenda

Matt Hancock’s ambition of an NHS shifting the NHS’s resources from treatment to prevention also appears to be backed by parliamentarians. 69 per cent of MPs believe the NHS should “direct more resources towards prevention, rather than increasing funding for new treatments.” This is 5% higher than when this question was asked a year previously, suggesting growing support for the prevention agenda.

Medicines access

MPs also believe that patients in the UK get good access to the medicines that can treat them best.

More than two thirds (67%) of MPs agreed with this statement, particularly Conservative MPs, with 79% stating this is the case. And just 25% of MPs believe improving the availability of new medicines on the NHS is a top funding priority.

This is despite a steady drumbeat of medicines access issues being raised throughout the last parliament, such as that of Orkambi.

Labour’s high-profile General Election focus on medicines pricing and life sciences companies being part of Brexit trade talks isn’t reflected by the Parliamentary Labour Party, with more than half (52%) of Labour MPs stating that patients get good access to medicines.

 

To discuss the wider findings and what they mean for your business in more detail, please contact Caroline Gordon, WA’s Director and Head of Health, at carolinegordon@wacomms.co.uk.

 

The polling was conducted by YouGov between 8th and 23rd January 2020. 101 MPs were polled, including 40 from the Conservative Party and 40 from the Labour Party.

 

 

Share this content:

Register for insights

Speak to us
020 7222 9500 contact@wacomms.co.uk

6th Floor, Artillery House
11-19 Artillery Row
London
SW1P 1RT
close_pop
Sign Up
Complete the form below to sign up to our newsletter:

    YOUR NAME:

    EMAIL:

    ORGANISATION:


    By submitting this form you agree to WA Communications’ Privacy Policy.